Harmony Biosciences Hldgs Earnings Review: Q4 Summary
Benzinga Insights 8 months ago
Earnings
The earnings results for Harmony Biosciences Hldgs (NASDAQ:HRMY) for Q4 were made public on Tuesday, February 24, 2026 at 07:30 AM.
Here's a comprehensive overview of the announcement.
Earnings
Harmony Biosciences Hldgs missed estimated earnings by -41.84%, reporting an EPS of $0.57 versus an estimate of $0.98.
Revenue was up $42.51 million from the same period last year.
Analysis of Past Earnings
Last quarter the company beat on EPS by $0.2 which was followed by a 2.05% increase in the share price the next day.
Here's a look at Harmony Biosciences Hldgs's past performance:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | 0.88 | 0.89 | 0.91 | 0.82 |
| EPS Actual | 1.08 | 0.92 | 1.03 | 1.08 |
| Revenue Estimate | 225.19M | 203.72M | 182.27M | 201.25M |
| Revenue Actual | 239.46M | 200.49M | 184.73M | 201.27M |
To track all earnings releases for Harmony Biosciences Hldgs visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.